Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Aarti Pharmalabs, demerged from Aarti Industries in 2022, manufactures active pharmaceutical ingredients, pharma intermediates and xanthine derivatives such as caffeine and its salts. It supplies domestic and global formulation companies and also operates a CDMO/custom synthesis stream. Revenue is driven by API and xanthine volumes, with caffeine derivatives serving pharma as well as food and beverage customers.
One of the few large-scale xanthine-derivative (caffeine) producers globally alongside its API business.
Aarti Pharmalabs Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Aarti Pharmalabs Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 19.27 | 30.06 | 23.93 |
| Book value / share (₹) | 234.35 | 219.55 | 193.88 |
| Return on equity | 8.1% | 13.7% | 12.3% |
| Return on capital employed | 10.4% | 16.8% | 16.6% |
| Operating margin | 14.6% | 17.9% | 16.9% |
| Net margin | 9.6% | 12.9% | 11.7% |
| EBITDA | ₹369 Cr | ₹464 Cr | ₹386 Cr |
| Free cash flow | ₹-147 Cr | ₹-70 Cr | ₹18 Cr |
| Total debt | ₹686 Cr | ₹396 Cr | ₹264 Cr |
| Debt to equity | 0.32 | 0.20 | 0.15 |
| Interest coverage | 5.7 | 14.0 | 18.2 |
| Current ratio | 1.49 | 2.01 | 1.94 |
| Shares outstanding | 9,06,57,800 | 9,06,34,600 | 9,06,26,000 |
Open the full income statement, balance sheet and cash flow for AARTIPHARM →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.